Pointe Scientific Inc.

Recipient: Pointe Scientific Inc.
Product:Hemoglobin A1c, Liquid Glucose Hexokinase, Liquid Alkaline Phosphatase, Liquid Auto Density Lipoprotein (Auto HDL) Cholesterol and other chemical analyzersr
Date: 8/11/06

Failure to maintain procedures to ensure that the specified design requirements are met; failure to review all complaints to determine whether an investigation is necessary; failure to maintain procedures for implementing corrective and preventive actions; failure to establish complete procedures for investigating the cause of nonconforming products; failure to maintain complete Device Master Records; failure to validate manufacturing processes; failure to establish procedures and monitor production process parameters; failure to validate computer software used to control automated production and quality system operations; failure to conduct quality audits; failure to follow procedures for controlling the storage of products in order to prevent adverse effects; failure to adequately train employees; failure to maintain adequate medical device reporting procedures; and failure of management with executive responsibility to ensure that an effective quality system has been implemented at all levels of the organization.
Letter acknowledges receipt of company’s July 2006 response to FDA 483 but deems it inadequate.

Your firm failed to validate computer software used to control automated production and quality system operations, as required by 21 CFR 820.70(i). For example, your firm has not validated the software used to produce labels and manage your complaints.

FDA District: Baltimore District Office

Schedule Discussion with John F. Murray, Jr.

John is currently providing telephone and face-to-face meetings to discuss:  Cybersecurity, Part 11, 483 Response, design controls expectations for software documentation, and other topics.

Leave a message and we will contact you to schedule:

Corporate Office

Partners located in the US (CA, FL, MA, MN, TN) and Italy.